FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
The FDA said it will now review only a small number of emergency use authorization (EUA) requests for COVID-19 diagnostic…
No More Free COVID-19 At-Home Tests, Federal Government Says
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au
Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks Instead
Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.
BTIG Maintains Buy on Exact Sciences, Lowers Price Target to $70
BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $100 to $70.
Raymond James Maintains Outperform on Exact Sciences, Lowers Price Target to $70
Raymond James analyst Andrew Cooper maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and lowers the price target from $80 to $70.
Exact Sciences Q2 EPS $(0.90) Beats $(1.07) Estimate, Sales $521.64M Beat $497.50M Estimate
Exact Sciences (NASDAQ:EXAS) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(1.07) by 15.89 percent. This is a 12.62 percent increase over losses of $(1.03) per share from